Podocytes are the major source of IL-1α and IL-1β in human glomerulonephritides  by Niemir, Zofia I. et al.
Kidney International, Vol. 52 (1997), pp. 393—403
Podocytes are the major source of IL-la and IL-113 in human
glomerulonephritides
ZOFIA I. NIEMIR, HENNING STEIN, GRZEGORZ DwoRAciu, PETER MUNDEL, NADJA KOEHL, Boius KOCH,
FRANK AUTSCHBACH, KONRAD ANDRASSY, EBERHARD RITZ, RUEDIGER WALDHERR, and HERWART F. Orro
Departments of Pathology, Nephrology and Anatomy, Ruperto-Carola University, Heidelberg, Germany, and Department of Pathology,
Poznan Medical Schoo4 Poland
Podocytes are the major source of IL-la and IL-lf.3 in human glomer-
ulonephritides. To address the question of in situ production of IL-la and
IL-l/3 in proliferative and non-proliferative forms of human glomerulo-
nephritis (UN), we performed immunocytochemical and in situ hybridiza-
tion studies on renal biopsies from patients with mesangial IgA-GN (N
38), idiopathic membranous GN (MGN; N 12), minimal change disease
(MCD; N = 9), focal segmental glomerulosclerosis (FSGS; N = 5) and
acute endocapillary UN (AGN; N = 3). Normal kidneys (N = 10) served
as controls. Concomitantly, the expression of IL-I receptor type I (IL-i
RI), IL-I receptor type II (IL-i Ru) and of IL-i receptor antagonist (IL-I
RA) was analyzed. Antibodies against antigens expressed on podocytes
(PP-44), endothelial cells (CD3I) and monocytes/macrophages (CDilb,
CD 14, CD68) were applied to attribute the expression of IL-i/IL-I related
peptides to intrinsic glomerular and/or blood-derived infiltrating cells. Our
results demonstrate that IL-i Rh is constitutively expressed on endothe-
hal cells, and its expression can be induced in proximal tubular cells and
in the interstitium. In diseased glomeruli podocytes are capable of
producing IL-la/13. In MGN and MCD/FSGS, the expression of both IL-i
forms is particularly noted in early stages of the disease and is not only
accompanied by a marked reactivity for IL-i RI, but also for IL-I RA. In
segmental sclerosing lesions in FSGS and in IgA-GN with marked
glomerular proliferation and/or sclerosis, a reduced expression of the
PP-44 antigen and a diminished ability of podocytes to produce IL-i/IL-i
related peptides are noted. These results suggest that intrinsic glomerular
production of IL-i may be of relevance for the protection of glomeruli
from continuing injuly.
Among inflammatory cytokines IL-i represents a central medi-
ator of inflammation [1]. IL-I has been shown in glomeruli in
severe forms of human and animal UN [2—6]. In vitro, mesangial
cells stimulated with immune complexes produce this cytokine [7].
Recently, it has also been suggested that visceral epithelial cells
are capable of producing IL-lp in glomerular inflammation [5].
The production of IL-i in chronic proliferative forms of human
UN, however, has mainly been attributed to infiltrating blood-
derived monocytes/macrophages [8—101. On the other hand, an
increased excretion of IL-i in the urine has been described in
patients with idiopathic membranous UN, where proliferation of
glomerular cells is absent or minimal and a significant number of
infiltrating cells is not observed in glomeruli [ii].
Restriction of the IL-i action in accelerated nephrotoxic ne-
phritis in the rat by infusion of recombinant IL-i receptor
antagonist (IL-i RA) reduced glomerular injury [12]. Exogenous
IL-I RA, however, was without effect in the established murine
lupus nephritis and a modulating role of endogenously produced
IL-i RA for IL-i expression has been suggested [131. Indeed, a
coordinated expression of IL-1/3 and IL-RA genes has been
shown in glomeruli after the induction of antibody-mediated UN
in rats [6]. We examined the in situ production of IL-la and 1L-1f3
in renal biopsies from patients with various forms of proliferative
and non-proliferative UN by means of immunocytochemistry and
in situ hybridization. The expression of peptides blocking IL-i
binding to the IL-i signal IL-i receptor type I (IL-i RI) [14], or
the IL-i receptor type II (IL-i RII) [15, 16] and IL-i RA [17] was
analyzed at the protein level.
In an attempt to attribute the expression of these peptides to
intrinsic glomerular and/or blood-derived infiltrating cells, immu-
nocytochemical staining with monoclonal antibodies reacting with
specific glomerular and infiltrating cells' antigens was performed.
Recently, two glycoproteins, that is, CD3 1 and PP-44, have been
shown to be exclusively expressed by endothelial and visceral
epithelial cells, respectively [18—20]. CD31, platelet-endothelial
cell adhesion molecule (PECAM), represents an adhesion mole-
cule involved in the formation of intercellular junctions that is
constitutively expressed on endothelial cells [18, 19]. PP-44 has
been localized to podocyte foot processes and is assumed to be
involved in the podocyte contractile apparatus [20]. Concomi-
tantly, the expression of cell surface molecules characteristic of
monocytes/macrophages, particularly those implicated in leuko-
cyte-mesangial and endothelial-leukocyte adhesion, was studied.
Our results clearly demonstrate that in glomerular disease
IL-la and IL-f3 are produced in glomeruli and their production is
tightly regulated.
METHODS
Patients
Sixty-seven patients were enrolled in this study: 38 with mesan-
gial IgA-glomerulonephritis (IgA-UN; 10 females, 28 males,
median age 37.6, range 8 to 71 years), 9 with minimal change
disease (MCD; 4 females, 5 males, median age 19.2, range 5 to 47
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Table 1. Histological and clinical data of patients at the time of renal biopsy
Glomerular
obsolescence!
Crescents sclerosis
Age
No. years/sex %
Duration of
symptoms
years
Serum
creatinine
mg!dl
Urinary
protein
g/24 hr
Urinary
erythrocytes
E/mm3
IGA-GN
MGA
1 15/Ma 4/12 0.9 0.5 30,000
2 21/M 2 0.9 0.3 gross hematuria
3 27/Me 6/12 1.2 0.3 317,000
4 20!M 3/12 0.9 0.4 gross hematuria
MesPGN
5 49/Ms — — unknown 1.0 2.4 50,000
6 43/F — — unknown 0.8 NS 15,000
7 36/F 11 22 2 1.1 0.5 5,000
8 19/M — — unknown 0.8 0.9 gross hematuria
9 20/Ma — — 1.5 0.9 3.0 30,000
10 71/M — — unknown 2.1 1.0 735,000
11 52/F 5 5 1.5 0.9 1.0 gross hematuria
12 11/M — — 1.5 0.8 2.0 22,000
13 44/F — — 2 0.8 0.5 gross hematuria
14 54/F — — 10 1.7 1.2 gross hematuria
CrGN
15 71/M 33 33 unknown 4.4 NS 30,000
16 44!M 50 — 2/12 1.7 NS gross hematuria
17 47/F 55 11 unknown 1.0 NS 10,000
18 36!M 33 — 1 1.0 3.0 gross hematuria
19 25!M 25 25 2 1.2 2.0 gross hematuria
20 12!M 50 50 2 1.0 NS gross hematuria
21 8/M 40 — 1 0.7 NS gross hematuria
22 40/Ms 35 14 1 0.9 2.0 30,000
23 33/Ms 36 18 1 1.0 3.5 20,000
ScGN
24 32/Ma — 88 unknown 1.8 2.7 100,000
25 49/Me — 50 15 2.0 4.1 gross hematuria
26 40/F 11 44 unknown 2.2 2.3 113,000
27 28/Fe — 44 1 1.5 NS 100,000
28 58/Ma 21 50 unknown 1.8 2.2 40,000
29 47/M — 60 1 1.6 3.0 100,000
30 57/M 20 50 unknown 9.0 2.5 gross hematuria
31 51/M 20 45 unknown 2.6 2.0 100,000
32 37/M 7 77 unknown 2.2 NS 260,000
33 56/M — 50 2 2.2 1.7 gross hematuria
34 68/Ms — 62 unknown 1.9 1.8 25,000
35 40/F — 43 unknown 1.8 4.0 gross hematuria
36 41/Fe — 40 20 1.0 3.5 20,000
37 21/Ms — 30 3 0.9 2.1 30,000
38 35/Jyfa — 30 7 1.0 1.5 50,000
MCD
39 6/Mb — 1 0.5 NS 10,000
40 10/F1' — 2 0.9 NS —
41 32/F — 1 0.8 NS 10,000
42 25/F — 1/12 0.6 NS 15,000
43 47/Me — 2 0.9 NS 10,000
44 71ph 3/12 0.9 NS —
45 31/Mb 5 0.9 NS —
46 5/Mb — 2 0.6 NS —
47 10/Wb 5 3/12 0.5 NS —
FSGS
48 9/Mb 15 (segm.) 8 0.9 NS 10,000
49 35/M 13 (segm.) 4 0.9 NS —
50 42/F 100 (scgm.) unknown 1.9 3.0 —
51 33/MU 77(segm.) 6/12 1.0 2.0 15,000
52 12/MU 89 (segm.) unknown 1.6 1.5 100,000
AGN
53 33/F — 2 weeks 2.4 0.5 gross hematuria
54 71/M 25 3 weeks 3.4 NS gross hematuria
55 22/MU — 1/12 1.0 5,000
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Table 1. Continued
Glomerular
No.
Age
years/sex
Crescents
obsolescence!
sclerosis
.Duration of
symptoms
years
Serum
creatinine
mg!dl
.
Urinary
protein
g/24 hr
.
Urinary
erythrocytes
E/mm3%
IMGN
56 7/M
Stage
I/I! — 4/12 0.6 NS 10,000
57 61/M II 12 3/12 1.0 NS 10,000
58 55/Ma II — 4/12 1.6 NS 100,000
59 40/Ms H — 3/12 0.9 NS
60 64/M lI/Ill 40 2 1.0 NS —
61 71/F" Il/Ill 33 7/12 1.6 NS 15,000
62 53/MC Il/Ill — 6/12 0.9 2.8 10,000
63 40/F Il/Ill — 1 0.7 NS 15,000
64 53/M Il/Ill — 6/12 0.9 2.8 —
65 77/M III 25 unknown 1.7 3.5 —
66 35/M III 83 3 9.0 NS 20,000
67 26/M III — 1.5 0.8 NS 10,000
Abbreviations are: MGA, minimal glomerular abnormalities; MesPGN, mesangial-proliferative GN; CrGN, mesangial-proliferative GN with
segmental crescents; ScGN, sclerosing GN; MCD, minimal change disease; FSGS, focal-segmental glomerulosclerosis; AGN, acute endocapillary GN;
IMGN, idiopathic membranous GN; NS, nephrotic syndrome.
a Patients/biopsies in whom in situ hybridization studies were performed
b Steroid-dependent NS
C Steroid and cyclophosphamide resistant NS
"Steroid-resistant NS
years), 5 with focal-segmental glomeruloscierosis (FSGS; I fe-
male, 4 males, median age 26.5, range 9 to 42 years), 3 with acute
endocapillary GN (AGN; 1 female, 2 males, median age 42, range
22 to 71 years) and 12 patients with idiopathic membranous GN
(IMGN; 2 females, 10 males, median age 56.2, range 7 to 71
years).
The diagnosis was based on conventional light and immunoflu-
orescence microscopy. Morphologically, patients with IgA-GN
presented with different degrees of mesangial expansion/prolifer-
ation and/or sclerosis with variable severity of tubulointerstitial
lesions. They were categorized as: minimal glomerular abnormal-
ities (MGA; N = 4), mesangial-proliferative GN (MesPGN; N =
10), mesangial-proliferative GN with segmental crescents (CrGN;
N = 9), and sclerosing GN (ScGN; N = 15) [21]. Histological
classification of IMGN was made according to the extent of
glomerular membrane alterations revealed by silver staining.
Systemic diseases were excluded by detailed clinical history,
examination and laboratory tests. Morphological, clinical and
laboratory data of the patients are summarized in Table 1.
Clinically, all patients exhibited a variable degree of proteinuria
and erythrocyturia, and normal or impaired renal function. Where
nephrotic range proteinuria (above 3.5 g/1.72 m2/24 hr) was
accompanied by hypoalbuminemia, dysproteinemia and lipid ab-
normalities, the designation of nephrotic syndrome (NS) was
used. Identified are patients biopsied for a revision of the
diagnosis due to ineffectiveness of the administered steroid and/or
steroid-cytotoxic treatment (Table 1).
In patients with AGN, a detailed clinical history revealed an
upper respiratory tract infection preceding two weeks to one
month the occurrence of urinary abnormalities. In two patients of
this group, the biopsy was performed during an early acute phase
of GN associated with renal function impairment. In the third
patient proteinuria was discovered accidentally, and the biopsy
was prescribed due to the presence of an upper respiratory tract
infection in his anamnesis and negative urine tests two months
prior to the biopsy.
Renal biopsies
Tissue preparations for conventional immunofluorescence mi-
croscopy, immunocytochemistiy and in situ hybridization were
performed as described elsewhere [21]. The immunocytochemical
studies were conducted on renal sections from all patients. Tissue
for in situ hybridization was available from 30 patients. Normal
appearing kidney tissue from patients undergoing tumor nephrec-
tomies (N = 10) and from kidneys refused for transplantation
(due to arterial connection problems; N = 2) served as controls
for both methods employed.
Immunocytochemistry
The following primary antibodies were applied in this study: a
murine monoclonal antibody to CD31 (0672; Immunotech, Mar-
seille, France), an anti-PP-44 monoclonal antibody (kindly pro-
vided by Dr. P. Mundel, Ruperto-Carola University, Heidelberg,
Germany) [20]), a murine anti-IL-la antibody (0795; Immuno-
tech), an anti-IL-113 monoclonal antibody (M 400; Immunotech),
a monoclonal mouse anti-IL-i receptor type I (CDwl2la) anti-
body (1592-01; Genzyme, Cambridge, MA, USA), an anti-IL-i
receptor type II mouse monoclonal antibody (1994-01; Genzyme),
a polyclonal anti-IL-i receptor antagonist antibody raised in goat
(BDA 29; R&D Systems, Minneapolis, MN, USA), amonoclonal
mouse anti-human monocyte CD14 (M 825, TUK4; Dako,
Glostrup, Denmark), a monoclonal antibody against CD lib (M
741; Dako) and a murine monoclonal antibody to CD68 (M 718,
EMB11; Dako). Acetone-fixed cryostat sections were stained with
all antibodies. The immunostaining procedure was performed on
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Fig. 1. The immunoreactivity for PP-44 in a normal glomerulus. The reaction is confined to the outer aspects of glomerular capillaries (X250).
Fig. 2. Biopsy from a patient with crescentic IgA-GN. Note the segmental loss of the PP-44 immunoreactivity on podocytes (X250).
Fig. 3. IL-i R II immunoreactivity in a normal glomerulus (control). A positive reaction is confined to endothelial cells of glomeruli, interstitial
capillaries and the afferent arteriole (X250).
Fig. 4. In situ hybridization using a digoxigenin-labeled IL-la antisense riboprobe in a normal glomerulus. IL-la transcripts are present in cells
localized in glomerular tufts and in capsular epithelial cells. Single periglomerular cells are also positive for IL-la (X250).
Fig. 5. IL-lp immunoreactivity in a biopsy specimen from a patient with IgA-GN and mild glomerular abnormalities. A positive reaction is mainly
confined to podocytes, outside glomerular capillaries. Tubular proximal epithelial cells are also positive (X250).
Fig. 6. In situ hybridization using an IL-i13 antisense riboprobe in a biopsy from a patient with IgA-GN and mild mesangial proliferation. Transcripts
for IL-113 are primarily localized outside mesangial areas, and furthermore, in tubular epithelial cells and some interstitial cells (X250).
Fig. 7. IL.i13 in membranous GN (stage 1111). A variable immunoreactivity is observed in two neighboring glomeruli. Positivity is limited to podocytes
(x250).
Fig. 8. IL-la immunoreactivity in a biopsy from a patient with membranous GN stage III and segmental sclerosis. Remaining podocytes disclose a
positive reaction (x250).
acetone-fixed cryostat sections using the APAAP (alkaline phos-
phatase anti-alkaline phosphatase) method as described previ-
ously [211. The only modification concerned the overnight incu-
bation of sections with the primary antibodies in the presence of
0.05% Tween-20 at —4°C.
Control experiments were conducted by omitting the incuba-
tion with the primary antibody and by substituting for the primary
antibody a non-immune murine or goat serum. In the case of
IL-113, an additional set of experiments after preincubation of the
antibody with a human recombinant IL-1f3 (G551A; Promega
Biotech, Madison, WI, USA) was performed. At the working
dilution of the antibody (1:200), the addition of 100 nglml of
rhIL-1f3 resulted in a negative staining even in biopsies with the
predominant immunoreactivity for IL-113.
In situ hybridization
Probe preparation. To generate riboprobes, respective cDNA
fragments were subcloned into pGEM (Promega Biotech, Madi-
son, WI, USA) and Bluescript II SK (Stratagene Ltd., La Jolla,
CA, USA) transcription vectors, A 460 bp HindIII-Avr II frag-
ment of the IL-113/YEpsecl plasmid (67024; ATCC, Rockville,
MD, USA) [221 was subcloned into HindIII-XbaI sites nf pGEM-
3z. A 396 bp fragment of coding frame for IL-la was subcloned
between the BamHI and EcoR I sites of BS II SK(+) [23]. The
templates were linearized with the appropriate restriction en-
zymes. Labeled antisense and sense cRNA probes were tran-
scribed in vitro using SP-6, T7 or T3 polymerases and digoxigenin-
labeled uridine-triphosphate (DIG-UTP) as substrate according
to the manufacturer's instructions (DIG RNA labeling kit; Boe-
hringer-Mannheim, Mannheim, Germany) [24].
In situ hybridization. The in situ hybridization studies were
performed as described previously [21] with some additional
steps. After acetylation, slides were rinsed in PBS (phosphate
buffered saline), immersed in 70% formamide/l >< SSC (sodium
saline citrate, 1 x SSC = 0.15 M NaC1 + 0.015 M sodium citrate,
pH 7.0), incubated at 75°C for five minutes, washed two times in
PBS and dehydrated in graded alcohol. The hybridization mixture
containing the respective cRNA probes was denatured at 65°C for
10 minutes. Immediately after application of this mixture onto the
slides, overnight hybridization in a humid chamber was per-
formed. Following hybridization, posthybridization washes in 1 x
SSC at the hybridization temperature and in 1 X SSC at room
temperature were done. Subsequent colorimetric detection, using
the DIG-Nonradioactive Nucleic Acid Detection Kit, was per-
formed as described previously [21].
Negative controls consisted of matched serial sections hybrid-
ized with sense probes and sections hybridized with unlabeled
antisense probes.
Evaluation of IL-i/IL-i related peptide expression
The expression of IL-la/ and IL-i related peptides in renal
biopsies at the protein versus mRNA level was scored by compar-
ing the localization and intensity of staining and/or number of
positive cells with their expression in normal renal tissue. The
expression of examined proteins/mRNAs was graded from 0 to 3
points according to the following scale: 0, no immunoreactivity/no
positive signals; 1, faint immunoreactivity/single positive cells; 2,
scattered moderately intense reactivity/numerous positive cells; 3,
dense intense immunoreactivity/clusters of positive cells.
RESULTS
Normal kidney
No differences were detected between the expression of exam-
ined peptides in normal appearing renal tissue from tumor
nephrectomies and donor kidneys. Thus, the designation "normal
kidney" comprises both sources.
The expression of PP-44 was exclusively confined to podocytes
(Fig. i). Endothelial cells of glomerular and interstitial capillaries
were positive for CD31.
A weak immunoreactivity for IL-1a/ was observed in glomerular
tufts and cells scattered throughout the interstitium. By in situ
hybridization, transcripts for IL-la//3 (Fig. 4) were detected in cells
localized to the glomerular tufts, in parietal epithelial cells, in
epithelial cells of distal tubules and in some cells in the interstitium.
The pattern of positivity for IL-i R II was identical to the
expression of CD31 (Fig. 3). A weak staining was additionally
observed in proximal tubular epithelial cells.
Only single cells scattered throughout the interstitium disclosed
a positive reaction for IL-i R type I.
Single cells positive for IL-i RA were seen in glomeruli, in
perivascular sites of interstitial vessels and in epithelial cells of distal
tubules.
CDiib, CD14 and CD68 positive cells (monocytes/macro-
phages) were only sporadically observed in glomerular tufts and in
the interstitium.
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Fig. 9. Biopsy from a patient with membranous GN (stage II). An intense
reactivity for IL-i RA is confined to the outer sites of glomerular
capillaries (x250).
LgA-GN
Compared to normal kidneys the most striking finding at the
protein level was a strong immunoreactivity for IL-1f3, confined to
outer aspects of glomerular capillaries (corresponding to the
immunoreactivity for PP-44), in biopsies with only minor glomer-
ular abnormalities (Fig. 5). Marked mesangial proliferation in
MesPGN and particularly in CrGN was accompanied by a re-
duced or even loss of PP-44 staining (Fig. 2) and a negligible
reaction for IL-113. In biopsies from patients with ScGN the
expression of IL-1/3 and PP-44 varied from glomerulus to glomer-
ulus. Only a trace reactivity for both peptides was observed in
sclerotic glomeruli, whereas in the remaining non-sclerotic gb-
meruli, the expression of IL-1f3 and PP-44 decreased dependent
on the extent of glomerular proliferative lesions.
In MGA, single cells in the interstitium were positive for IL-1f3.
In MesPGN and CrGN, positive cells were seen in clusters in
periglomerular infiltrates close to glomeruli with adhesions and
crescents. In MGA and MesPGN, staining for IL-i /3 was noted at
the apical membranes of proximal tubules (Fig. 5). Atrophic
tubules showed reduced staining or were completely negative.
An increased number of transcripts for IL-1f3 was noted in
glomeruli with mild mesangial proliferation (Fig. 6). In the
interstitium, IL-1/3 mRNA localized to areas of periglomerular
and interstitial mononuclear infiltration. Numerous transcripts for
IL-1f3 were found in epithelial cells of distal tubules irrespective of
the stage of the disease.
In contrast to IL-113, IL-la was nearly exclusively expressed in
glomerular cells and hardly noted in infiltrating cells in the
interstitium. The glomerular expression of IL-la corresponded to
that of IL-1f3. By in situ hybridization the expression of mRNA for
IL-la was similar to that observed for IL-113. Scans visualize the
difference between the number and intensity of signals in the
normal and diseased glomerulus (Fig. 11).
In glomenili, the immunoreactivity for IL-i R type II was
identical to that of CD31, and loss of positivity was related to the
degree of mesangial proliferation. Interstitial infiltrates disclosed
a positive reaction for IL-i R II. In MGA and MesPGN, basal
sites of tubular epithelial cells were positive.
A weak expression of IL-i R type I was observed in gbomerular
tufts in MGA and MesPGN. A faint interstitial staining was
detected when pronounced interstitial infiltration was present.
Fig. 10. Same biopsy as in Figure 9. Podocytes disclose a positive
reaction for IL-i R I (X250).
A positive glomerular reaction for IL-RA was noted in MGA,
MesPGN and to a lesser extent in CrGN. Infiltrates in the intersti-
tium were positive. In MGA and MesPGN, a diffuse staining for IL-i
RA was noted at the luminal sites of proximal tubular epithelial cells
whereas positivity varied in distal tubular cells.
Single cells positive for CD11b, CD14 and CD68 were found in
glomerular tufts in MGA and MesPGN. In MesPGN such cells
were often seen in small adhesions. In CrGN, cells positive for
CD1 lb were more commonly observed in glomerular tufts. These
cells were localized to glomeruli with pronounced mesangial
proliferation and seemed to be attached to podocytes surrounding
areas of proliferating mesangial cells. Monocytes/macrophages
were only occasionally detected in sclerotic glomeruli.
Some monocytes/macrophages were observed in the intersti-
tium in MGA. In MesPGN, focal infiltrates were additionally
noted in the vicinity of glomerular adhesions. This finding was
frequently observed in patients with CrGN and ScGN.
IMGN
The intensity of IL-i expression was related to the stage of the
disease. In biopsies with stage I and II a mild to pronounced
expression of IL-113 was observed in glomeruli from the same
tissue sample (Fig. 7). A scan of the last picture confirmed that the
outer aspects of glomerular capillaries were positive (Fig. 12; the
same analysis of PP-44 staining in the normal kidney is given for
comparison). In stages I/Il of IMGN, all gbomeruli exhibited a
significant reactivity for IL-ia, IL-i R type I (Fig. 10) and IL-i
RA (Fig. 9), corresponding to the pattern of podocyte staining.
Scanning exposed a much stronger reactivity for IL-i RA than
IL-i RI when the intensity of these reactions in the same tissue
(serial sections) was compared (Fig. 13). In biopsies from patients
with stage III disease, the immunoreactivity for PP-44 diminished
and concomitantly, the expression of IL-la//3 (Fig. 8), IL-i RI and
IL-i RA was also reduced.
The pattern of IL-i R II expression resembled that for CD31.
In proximal tubules, in addition to the positivity noted at the
luminal sites, basal sites of proximal epithelial cells exhibited a
positive reaction for IL-i R II.
In patients with IMGN stage Il/Ill infiltrates scattered through-
out the interstitium showed a positive reaction for IL-i/3 and
concomitantly, for IL-i RA and IL-I R II.
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Fig. 11. f r -la are detected in a normal glo erul s.   1  (  f r I -la) increases si ifi  early
stage f l r l r is s  (s s f i s.  and 6).
Fig. 12. Reactions for PP-44 and IL.lp are confined to the outer aspects of glomerular capillaries (scans of Figs. 1 and 7).
Fig. 13. The reactivity for IL-i RA significantly exceeds that for IL-i R I (serial sections from the same tissue; scans of Figs. 9 and 10).
MCD FSGS
The expression of all peptides examined was comparable to that Biopsies with FSGS were heterogeneous with respect to the
observed in IMGN stage I/Il. Glomeruli stained moderately for extent of sclerotic glomerular changes and tubulointerstitial alter-
IL-la/f3, IL-i R I, IL-i RA (podocytes) and for IL-i R II. ations. The expression of IL-la/f3, IL-i R I and IL-i RA in
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non-sclerotic glomeruli was similar to that observed in MCD. In
areas of segmental sclerosis, marked loss of PP-44 and CD31 was
noted and accompanied by only trace expression of IL-113 and
IL-i R II. Interstitial and proximal tubular epithelial staining for
IL-i R II and IL-i RA was strong in biopsies/areas with mild to
moderate alterations, whereas only faint positivity was observed in
areas with purely fibrotic interstitial changes. Interstitial infiltrates
disclosed a positive reaction for IL-1a/, IL-i RA and IL-i R II.
AGN
The expression of IL-i, IL-i R I and IL-i RA was largely
dependent on the degree of the proliferative response in glomer-
uli. In biopsies performed during an early stage of the disease, a
reduced staining for IL-1/3 and PP.44 on glomerular podocytes
was observed. In a patient subjected to the biopsy later in the
course of the disease an increase in the positivity for PP-44 along
with that for IL-1f3 was noted. The expression of IL-la, IL-i R I
and IL-i RA was very weak in the early stage of the disease and
increased slightly in a biopsy from a patient with a resolving stage
of AGN. A strong expression of IL-i R II was found in interstitial
Fig. 14. Semiquantitative evaluation of the
glomerular expression of IL-1o/I3 and IL-i
related peptides in all tissue specimens
examined. The score relates to the intensity of
immunocytochemical staining and/or the
number of positive cells. Asterisk (*) denotes
the expression of mRNAs, whereas (0)
identifies the respective proteins. Abbreviations
are: MGA, minimal glomerular abnormalities;
MesPGN, mesangial proliferative GN; CrGN,
mesangial proliferative ON with segmental
NK crescents; MCD, minimal change disease; AGN,
acute endocapillary GN; IMGN, idiopathic
membranous GN; NK, normal kidney.
areas. Interstitial infiltrates stained for IL-113, IL-i R II and IL-i
RA.
An increase in cells of monocyte/macrophage lineage was
observed in glomerular tufts in the early stage of the disease. In
the biopsy performed later, the number of cells positive for
monocyte/macrophage markers was comparable to the normal
kidney. These cells were relatively frequently noted in the inter-
stitium.
A semiquantitative evaluation of IL-la/13 and IL-i related
peptide expression in renal biopsies of all patients examined in
comparison to the expression noted in the normal kidney (accord-
ing to the grading system given in the Methods section) is
presented in Figure 14.
DISCUSSION
Our results demonstrating a constitutive expression of IL-i R II
on renal endothelial cells suggest an involvement of the kidney in
the protection against immunoreactive IL-i that may be present
in the circulation under any inflammatory conditions. IL-i recep-
tor type II expressed on the cell membrane has been shown to
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represent a "decoy" receptor that particularly binds IL-113 without
transducing a signal [15]. IL-lp represents an extracellular work-
ing form of IL-i [1, 25]. IL-1f3 produced as a 31 kDa peptide
requires activation by an intracellular cysteine protease processing
this peptide into an active 17 kDa molecule [25]. After intrave-
nous administration of radiolabeled IL-i/3, a rapid clearance of
this cytokine from the circulation is observed [261. Kidney, small
intestine and liver have been found to accumulate the highest
content of radioactivity [26]. The expression of IL-i R II on
endothelial cells in the kidney allows the assumption that this
molecule is also present on endothelial cells in other organs. Thus,
binding to the IL-i type II R may represent a physiological
mechanism of IL-113 inactivation and host protection.
Intriguingly, in phases of glomerular injury glomerular cells
themselves are capable of producing IL-la and IL-if3. The
pattern of immunoreactivity, identical with that of PP-44, points
to visceral epithelial cells as the main source of these cytokines.
The visualization of mRNA for IL-1a/ using in situ hybridization
confirmed their production in situ in the glomerulus. Although in
situ hybridization does not allow characterization of positive cells,
the localization and number of these cells (largely exceeding that
of cells of monocyte/macrophage lineage) permit the assumption
of intrinsic glomerular cell capability of producing IL-ia and
IL-113. The most pronounced expression of these cytokines is
associated with a generally well preserved glomerular structure
and only minor interstitial alterations present that point to the
early stages of glomerular diseases.
IL-la and IL-i/3 are devoid of signal propeptide allowing a
control of protein secretion [1, 23]. Regarding IL-lp, it has been
reported that it can only be released from cells under stress
conditions [27] or cells undergoing apoptosis [28]. In the light of
these data, podocyte staining for IL-1f3 might point to visceral
epithelial cell injury.
In IMGN stage I/Il and MCD an increased podocyte staining
for IL-1/3 is accompanied by an increased immunoreactivity for
IL-la, IL-i R type I and IL-i RA. IL-ia acts mainly intracellu-
larly and/or as a membrane-bound form [1, 29]. In contrast to
IL-Ip, IL-la does not require previous processing to the 17 kDa
molecule to be bound to IL-i R I for the signal transduction [301.
The presence of both forms of IL-i along with an increased
expression of IL-i R I in podocytes could identit' an autocrine
stimulation of IL-i production. On the other hand, however, a
concomitant expression of IL-i RA, which represents a restrictive
factor for the IL-i action [17], is noted in podocytes in these
biopsies. IL-i RA functions as a soluble molecule released from
cells and binding IL-ia/13 [17] or as an intracellular form that
inhibits IL-lp mediated responses [31, 32]. Both forms of IL-i RA
have been shown to be produced in epithelial cell lines [31, 32],
and they are indistinguishable by means of immunocytochemistry
[31]. In IMGN and MCD, an intense staining of podocytes for
IL-i RA, in addition to a diffuse positivity in the lumen of
proximal tubular epithelial cells, was observed. Therefore, the
production of both forms of IL-i RA in podocytes can be
supposed.
Recent results in mice overexpressing or lacking IL-i RA gene
demonstrate that endogenously produced IL-i RA was critical for
survival of Salmonella typhimurium-LPS induced endotoxemia,
but it impaired the host response to the infection with intracellu-
lar bacteria Listeria monocytogenes [33]. Intriguingly, it has been
found that IL-i RA acts as a positive regulator of IL-i in serum
during endotoxemia [33]. In the light of these results, podocyte
expression of IL-i RA may account for the modulation of IL-i
action, whereas binding of IL-i released from cells by a soluble
form of IL-i RA will limit a potentially toxic influence of IL-i on
neighboring cells.
In the latter context, concomitantly with the pronounced ex-
pression of IL-la/f3 in glomeruli in all patients with no or only
minor interstitial alterations, an immunoreactivity for IL-i R II in
proximal epithelial cells and interstitial cells was observed. An
increase in the IL-i R II reactivity was noted at the luminal and
basal sites of proximal tubular epithelial cells. The latter obser-
vation may point to in situ production of IL-i R II in proximal
epithelial cells, whereas positivity noted in the lumen of tubules
indicates a reabsorption of a soluble form of the receptor [16].
According to recent results, this particular molecule may be shed
from cells and can bind, as a soluble receptor, an active form of
IL-i/3 by blocking its access not only to the type I R, but also to the
IL-i13 precursor, thus preventing processing of IL-i/3 into its
mature form [16]. Moreover, in a soluble form it does not
interfere with inhibition of IL-1f3 action mediated by IL-i RA
[16].
The association of IL-1a/ expression with the presence of
peptides preventing IL-i action indicates the involvement of these
cytokines in mechanisms that allow the withstanding of injury.
Results demonstrating that both forms of IL-i can induce mem-
brane component production [34, 351 support this hypothesis.
IL-113 has been shown to induce the production of laminin B2
chain in cultured visceral epithelial cells [34]. Laminin is a major
non-collageneous component of the normal GBM that is involved
in cellular binding [36, 37]. IL-ia is a potent stimulator of collagen
type IV production [35], which is the basal form of collagen in the
normal GBM. Since IL-la represents mainly an intracellular
working molecule of IL-i [29], its increased expression may
particularly reflect mobilization of metabolic processes in podo-
cytes to limit glomerular basement membrane injury.
Interestingly, in IMGN stage I/Il and MCD, in parallel with an
increased expression of IL-ia, IL-i R I and IL-i RA, an increased
immunoreactivity for PP-44, a structural component of podocyte
contractile apparatus [20], is observed when compared to normal
control kidneys. The expression of PP-44, IL-I and IL-i related
peptides decreases along with the disruption of glomerular archi-
tecture observed in advanced stages of glomerular disease. Studies
in experimental glomerular diseases indicate a crucial role of
podocytes for the preservation of glomerular architecture and
function [38, 39]. Podocytes are postmitotic cells with only a
limited potential for cell division [38, 40]. The inability to replace
diseased podocytes is thought to be decisive for the occurrence of
GBM denudation leading subsequently to synechia formation
initiating sclerotic alterations [38, 39]. Although further studies
addressing this issue are required, it seems conceivable that IL-I
mediated mobilization of podocyte metabolic processes is aimed
at preservation of podocyte contractile functions to maintain the
appropriate capillary wall tension [411.
In conclusion, our results demonstrate that IL-la and IL-i/3 are
produced by podocytes in glomerular inflammation, in contrast to
previous results suggesting predominantly harmful effects of these
peptides, we propose that IL-ia/f3 also represent modulators of
regulatory processes preventing lethal injury to podocytes.
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